Health

The Longevity Marketplace, Decoded: What They’re Selling, and What the Evidence Says

Senolytics, NAD, NMN, and five-figure clinics. A seven-part guide to the longevity market: who is talking, what they are selling, and what the trials actually show.

Todd Ruffner-Schoenfeld Editor in chief. A knack for the fine print, and likes it. 22 Aug 2026 2 min read 4 sources E.G. v4.17

A single orange-and-white medication capsule on a plain white surface. — The market runs on pills and promises. Photo: Christina Victoria Craft / Unsplash.

There is a lot of money in wanting to live longer. The same commercial forces that shape a search result and a supplement label run all the way down to clinics charging five figures a year. This guide walks the longevity marketplace one product and claim at a time, and holds each against the actual evidence.

Each part takes a single piece of the market, senolytics, NAD, NMN, the clinics, and asks the same two questions: what is being sold, and what do the trials really show? Read in order for the full picture, or jump to the product someone is trying to sell you.

The short version

Before the evidence, look at who is doing the talking. The market’s incentives shape the science you hear about it.
The biology behind senescence and NAD is real. The retail versions, daily capsules and clinic protocols, run well ahead of what the human trials support.
The human data on senolytics and NMN are real but early, small, and short of clear results on hard endpoints. The gap between that and the marketing is the whole story.

The marketplace, piece by piece

Who is doing the talking. Start here. The same forces that shape search results and supplement labels run down to five-figure clinics. Before any evidence, look at who is talking.

Senescence, explained properly. Senescent cells get called zombie cells that poison their neighbors. The biology is real; the marketing version is simplified past usefulness. The clearer picture.

The human evidence on senolytics. Animal studies showed clearing senescent cells can improve healthspan. The human data are real but early, small, and short of clear efficacy. What the trials showed.

Products vs. protocols. The trials used intermittent, high-dose, supervised regimens. The retail market sells daily capsules. Why the product and the protocol are not the same thing.

The NAD-decline story. The NAD-decline narrative is the engine behind a lot of sales. What it gets right, and where it outruns the evidence.

NMN and NR, in the trials. NMN and NR are the supplements built on that story. What the human trials on them have, and have not, shown.

What the clinics sell. Longevity clinics charge five figures a year. What that money actually buys, and what the evidence says about the results.

Where to start

Start with “The Search Results Are the Story” to see the incentives, then read the product you are being sold. If you read only one, make it the “products vs. protocols” piece; it is the pattern the whole market repeats.

Sources

Reported and edited to HeadLines Decoded newsroom standards. E.G. v4.17 · I.R.G. v1.14 · L.R.G. v1.9 · P.L.G. v1.10 · SEO G. v1.6 · AI Detection Gate v1.1. This is health information, not medical advice; decisions about your health belong with you and your clinician. This is the hub for our seven-part The Longevity Marketplace series; each part is linked above.

Written by Todd Ruffner-Schoenfeld Editor in chief. A knack for the fine print, and likes it.

Todd Ruffner-Schoenfeld has spent his working life being handed things he did not yet understand. He started at the bottom, a developer in a bullpen, and worked his way up to running IT. The places were a strange assortment: consulting firms, accounting firms, a biotech startup, a tech startup in Silicon Valley and, of all places, Chiquita. Four small businesses of his own along the way. The work never really changed. Get into something unfamiliar, find out what is actually going on, and help someone make a hard decision with it. HeadLines Decoded is that job, pointed at the news.